Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ultragenyx Pharmaceutical Inc.
  6. News
  7. Summary
    RARE   US90400D1081

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00:00 2023-03-24 pm EDT
37.68 USD   +1.87%
03/23Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
03/23Ultragenyx Pharmaceutical Inc. Announces Retirement of Lars Ekman as Board of Directors
CI
03/22Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HC Wainwright Assumes Ultragenyx With Buy Rating, $82 Price Target

12/30/2022 | 07:29am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about ULTRAGENYX PHARMACEUTICAL INC.
03/23Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
03/23Ultragenyx Pharmaceutical Inc. Announces Retirement of Lars Ekman as Board of Directors
CI
03/22Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
03/21Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
03/14Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
03/14Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
GL
03/14Ultragenyx Pharmaceutical Inc. Appoints Dr. Eric Crombez Chief Medical Officer and Exec..
CI
03/07Transcript : Ultragenyx Pharmaceutical Inc. Presents at Cowen 43rd Annual Hea..
CI
03/01Ultragenyx pharmaceutical to participate in orphan neuro panel at cowen healthcare conf..
AQ
02/28Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
GL
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2023 435 M - -
Net income 2023 -562 M - -
Net cash 2023 471 M - -
P/E ratio 2023 -4,81x
Yield 2023 -
Capitalization 2 646 M 2 646 M -
EV / Sales 2023 5,00x
EV / Sales 2024 4,27x
Nbr of Employees 1 311
Free-Float 94,9%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 37,68 $
Average target price 90,58 $
Spread / Average Target 140%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Samuel C. Wadsworth Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-18.67%2 646
REGENERON PHARMACEUTICALS, INC.13.65%87 515
VERTEX PHARMACEUTICALS8.87%80 827
WUXI APPTEC CO., LTD.-1.06%34 805
BIONTECH SE-14.66%31 155
GENMAB A/S-12.34%24 291
Stock markets for all
100% Free Registration
fermer